HeartFlow Analysis vs ElucidVivo A.3
AI Verdict
Choose HeartFlow Analysis if…
Choose HeartFlow Analysis if you require a comprehensive, non-invasive solution for diagnosing and managing coronary artery disease, particularly when assessing the functional significance of blockages. Its AI-powered FFRct analysis and 3D modeling provide crucial insights into blood flow dynamics, aiding in revascularization decisions and overall patient management.
View HeartFlow Analysis →Choose ElucidVivo A.3 if…
Choose ElucidVivo A.3 if your primary need is a detailed, quantitative analysis of arterial plaque composition and stability to stratify atherosclerosis patients and optimize treatment. This tool excels at objectively quantifying specific plaque components like Lipid-Rich Necrotic Core (LRNC) and calcifications, offering histology-validated insights into plaque vulnerability.
View ElucidVivo A.3 →When choosing between HeartFlow Analysis and ElucidVivo A.3, physicians should consider their primary diagnostic focus in coronary artery disease (CAD). HeartFlow Analysis excels at providing a comprehensive, non-invasive functional assessment of coronary arteries. Its core strength lies in creating personalized 3D models from CT scans to derive Fractional Flow Reserve (FFRct) and quantify plaque, offering insights into blood flow and the hemodynamic significance of blockages. This makes it particularly well-suited for physicians needing to understand the functional impact of CAD and guide decisions on revascularization, with established Medicare and commercial payer coverage and dedicated CPT codes for its FFRct and AI-enabled plaque analysis.
ElucidVivo A.3, in contrast, specializes in the detailed quantitative analysis of arterial plaque composition and stability. While it also offers FFRct based on vessel wall vasodilative capacity, its key practical difference is its focus on objectively quantifying specific plaque components like Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications, validated against histology. This detailed plaque characterization is invaluable for stratifying patients with atherosclerosis and optimizing treatment decisions based on plaque vulnerability. Therefore, physicians prioritizing a deep understanding of plaque morphology and composition for risk assessment and medical management may find ElucidVivo A.3 more aligned with their needs, whereas those primarily focused on the functional significance of stenoses for interventional planning may lean towards HeartFlow Analysis.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | HeartFlow Analysis | ElucidVivo A.3 |
|---|---|---|
| Pricing | Contact vendor for pricing | Contact for pricing |
| Deployment | Cloud-based (AWS) | Software application, likely on-premise or cloud-based (standard for medical imaging software, not explicitly detailed, but integrates with PACS/EMR). |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Yes AI-estimated | 1 AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
HeartFlow AnalysisHeartFlow Analysis explicitly states a 'Cloud-based (AWS)' deployment, which generally offers superior accessibility, scalability, and reduced IT overhead for users compared to traditional on-premise solutions. While ElucidVivo A.3 integrates with PACS/EMR, its deployment is less clearly defined, potentially implying a more traditional software installation.
Clinical Value
HeartFlow AnalysisHeartFlow Analysis offers both FFRct and Plaque Analysis, with established Category I CPT codes and CMS payment rates, indicating broad clinical acceptance and reimbursement. Its focus on 'High diagnostic accuracy' and 'Computational Fluid Dynamics (CFD) for blood flow simulation' provides a comprehensive functional and anatomical assessment for CAD. While ElucidVivo A.3 provides valuable detailed plaque characterization validated against histology, the established reimbursement and widespread adoption of HeartFlow's FFRct give it a slight edge in immediate clinical utility and financial viability for providers.
Pricing & Value
HeartFlow AnalysisHeartFlow Analysis clearly outlines a fee-for-service model that is covered by Medicare and most U.S. commercial payers, with established Category I CPT codes and CMS payment rates. This transparency and established reimbursement pathway significantly enhance its value proposition for healthcare providers. ElucidVivo A.3, while offering valuable features, does not provide any information regarding CPT codes or reimbursement, making its financial integration less clear.
Enterprise Readiness
HeartFlow AnalysisHeartFlow Analysis explicitly states 'yes' for HIPAA compliance, BAA availability, and FDA clearance, alongside a 'Cloud-based (AWS)' deployment, which are all critical for enterprise adoption, data security, and scalability. ElucidVivo A.3's HIPAA compliance and BAA status are not explicitly stated, and its deployment model is less detailed, which could present more questions for enterprise IT departments.
Innovation
ElucidVivo A.3While HeartFlow pioneered FFRct, a significant innovation in non-invasive CAD assessment, ElucidVivo A.3 demonstrates a distinct and highly advanced form of innovation. Its ability to objectively quantify specific plaque components like Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images, validated against ground-truth histology, offers a deeper and more precise understanding of plaque stability and patient stratification. This detailed, histology-validated plaque characterization pushes the boundaries of non-invasive atherosclerosis assessment.
Support & Docs
TieNeither the provided structured facts nor general web searches revealed specific, differentiating details regarding the quality, extent, or accessibility of support and documentation for either HeartFlow Analysis or ElucidVivo A.3. Both companies appear to offer standard customer support channels, making it difficult to declare a definitive winner in this dimension without more granular information.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | HeartFlow Analysis | ElucidVivo A.3 |
|---|---|---|
| Company | HeartFlow | Elucid Bioimaging |
| Product Name | HeartFlow Analysis | ElucidVivo A.3 |
| Description | Commercial-stage medical technology company providing software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease (CAD) by creating personalized 3D models of patients' coronary arteries from standard CT scans. | FDA-cleared AI-powered medical image analysis system that provides quantitative analysis of arterial plaque composition and stability from CT angiography. It assists physicians in atherosclerosis patient stratification and optimizes treatment decisions by offering detailed visualization and measurement of plaque characteristics validated against histology. |
| Key Features (Plaque Analysis) | Plaque Analysis (quantification and characterization) | AI-powered quantitative analysis of arterial plaque; Objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images; Visualizes lesion-level plaque composition; Provides 3D visualization of highlighted vessels; Offers rotatable curved MPR vessel views and cross-sections; Validated on ground-truth histology |
| Key Features (FFRct) | Fractional Flow Reserve derived from CT (FFRct) analysis | Derives fractional flow reserve (FFRct) based on vessel wall vasodilative capacity |
Videos
Demos, reviews, and walkthroughs featuring HeartFlow Analysis and ElucidVivo A.3.